Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Genevant Sciences Inc.

Genevant Sciences aims to deliver innovative and clinically meaningful therapies that improve the lives of patients with genetic disorders by developing products in-house and forming partnerships to build a diverse pipeline of RNA therapeutics across multiple modalities. Through its proprietary delivery platforms, Genevant is able to pursue mRNA, RNAi, and gene editing modalities and select the optimal approach for any given disease. Genevant expects to have 5 to 10 RNA programs in the clinic by 2020 targeting a range of genetic disorders with limited or no treatment options. *

 

Period Start 2018-07-10 existent
  Group Roivant (Group)
Products Industry RNA-based therapeutic
  Industry 2 mRNA technology
Person Person Panayiotopoulos, Paris (Roivant 201807 Executive Chairman of Genevant before Ariad 201606 CEO)
     
Region Region Cambridge, MA
  Country United States (USA)
  City n. a. 
    Address record changed: 2018-07-10
     
Basic data Employees n. a.
     
    * Document for �About Section�: BioNTech AG. (7/10/18). "Press Release: BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases". Mainz, Cambridge, MA & Basel.
     
   
Record changed: 2018-10-31

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Roivant (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top